El ISP llama a la poblacin a abstenerse de adquirir los PATCHES GLP-1 y recomienda a la comunidad tomar las siguientes medidas, con el fin de minimizar los riesgos asociados al uso de este producto: A
Most clients begin to notice fewer food cravings and more satiation, or fullness, immediately
For patients with type 2 diabetes, NICE guidance recommends that GLP-1 treatment should be continued only if there is adequate improvement in HbA1c and weight after 6 months
Safety and Contraindications Mounjaro and Wegovy are not recommended for individuals with a history of: Medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) Severe gastrointestinal disorders Pancreatitis Pregnancy or breastfeeding (Safety data is limited) Severe kidney or liver disease (Caution required) Cost and Insurance Coverage For weight loss solutions Elevate Now is one of the leading platforms where doctors assess eligibility, identify underlying factors, and guide you with medically supervised GLP-1 alternatives
Ilya Zhivkovich for their helpful discussion during the design of the study
The biggest benefit is convenience for patients who dislike needles